The TRANQUILITY 2 Trial: A Phase 3 Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Study sponsor: Aldeyra Therapeutics, Inc. · ALDX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-03-04Actual
Enrollment · participants361Actual
Source updated2025-03-18Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.